SLC7A11 and breast carcinoma: Our results thus far suggest that xCT positive breast cancer cells—Those expressing high levels of both SLC7A11 and SLC3A2—Are able to drive GPX4 expression through the selenocysteine biosynthesis pathway, and also are able to resist lipid prooxidant-induced death.